Clinical trials: Dementia, completed
Agitation, Psychosis
Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone
Behavioral and psychological symptoms of dementia (BPSD) are among the most distressing manifestations of dementia. Pharmacotherapy is frequently used and especially in institutional settings.
- Conditions
- Agitation, Psychosis, Alzheimer's Disease
- Trial name
- EscBPSD (NCT01119638)
- Testing
- Escitalopram, Risperidone
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Abarbanel Mental Health Center
Alzheimer Disease
Effects of Heart Rate Oscillations During Meditation on Plasma Biomarkers of Alzheimer's Disease
In the current study, we will examine how two types of concentration meditation practices affect plasma biomarkers of Alzheimer's Disease (AD).
- Trial name
- NCT06210035
- Testing
- Belly-focus meditation, Belly-focus meditation with slow breathing
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Cognitive Impairment, Cognitive Decline
Multicentre Study About the Effect of Individual Reminiscence Therapy
This study aims to evaluate the effect of individual reminiscence therapy (RT) on the global cognitive function of people with neurocognitive disorders attending social responses and to evaluate the ability of individually…
- Conditions
- Cognitive Impairment, Cognitive Decline, Dementia, Neurocognitive Disorders
- Trial name
- NCT04047238
- Testing
- Reminiscence Therapy
- Where
- 25 sites in Portugal
- Volunteers
- 251 people
- Sponsor
- Rsocialform - Geriatria, Lda
Alzheimer's Disease
A Study of SHR-1707 in Healthy Young Adult and Elderly Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single intravenous administration of SHR-1707 in healthy young adult and elderly subjects.
- Trial name
- NCT04973189
- Testing
- SHR-1707
- Where
- China
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Alzheimer Disease
Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease
Evaluate safety, tolerability, and pharmacokinetics of single doses of the investigational AAB-001 Vaccine in Japanese patients with Alzheimer's disease.
- Trial name
- NCT00397891
- Testing
- bapineuzumab
- Where
- 4 sites in Japan
- Volunteers
- 80 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer's Disease
Pathological and Non-pathological Aging, Physical Activity, Genotype and Cognition
Alzheimer's disease (AD) is an irreversible, progressive brain disease. It is the most common form of dementia and the major cause of functional dependence in the elderly.
- Trial name
- VIAGECO (NCT02520232)
- Testing
- Combination of aerobic and strength exercises, Stretching and balance exercise program
- Where
- 2 sites in France
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Alzheimer Disease
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
The purpose of this study is to provide healthy adults with genetic testing and information about their chances of developing Alzheimer's disease.
- Trial name
- REVEAL (NCT00462917)
- Testing
- Pleiotropic info, in-person disclosure, AD-only info, in-person disclosure, Pleiotropic info, phone disclosure
- Where
- 4 sites in United States
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Presbycusis, Bilateral, Alzheimer Disease 2 Due to Apoe4 Isoform
Hearing Aid and Individuals With Cognitive Disorders
This is a pilot study with the aim of evaluating the feasibility of the procedures of a future clinical trial that will help determine the impacts of hearing aid interventions on older patients with Alzheimer's Disease and…
- Conditions
- Presbycusis, Bilateral, Alzheimer Disease 2 Due to Apoe4 Isoform, Mild Cognitive Impairment
- Trial name
- NCT04049643
- Testing
- Audiologist-based fitting, Service-only Fitting, Device-only fitting
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Yu-Hsiang Wu
Mild Cognitive Impairment, Obesity
Caloric Restriction in Obese Patients With Mild Cognitive Impairment: Effects on Adiposity, Comorbidity and Cognition
Obesity has been associated with cognitive impairments, lower blood flow, metabolic activity and brain volume. Obesity in adulthood is a risk factor for Alzheimer's disease in the elderly.
- Trial name
- NCT01286389
- Testing
- medical care, caloric restriction
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- University of Sao Paulo General Hospital
Amyloidosis
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
The drugs dexamethasone and bortezomib are both FDA-approved for the treatment of multiple myeloma, a disease very similar to amyloidosis. However, they are currently investigational for the treatment of amyloidosis.
- Trial name
- NCT01083316
- Testing
- Bortezomib, Dexamethasone, Melphalan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Boston Medical Center
Late Onset Alzheimer Disease
Response to Donepezil, Drug Plasma Concentration and the CYP2D6 and APOE Genetic Polymorphisms
Pharmacological treatment of AD is currently based on cholinesterase inhibitors (ChEI) and memantine, which have been shown to lead to modest, although effective, clinical benefits.
- Trial name
- NCT03349320
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of clenbuterol (CST-103) co-administered with nadolol (CST-107) in 4 subject populations with…
- Trial name
- CLIN-011 (NCT04739423)
- Where
- 7 sites in Australia, New Zealand and 1 more
- Volunteers
- 41 people
- Sponsor
- CuraSen Therapeutics, Inc.
Alzheimer's Disease
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine in a 12-week treatment study if MEM 1003 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00257673
- Testing
- MEM 1003
- Where
- 57 sites in United States
- Volunteers
- 183 people
- Sponsor
- Memory Pharmaceuticals
Alzheimer Disease
Gene Therapy for Alzheimer's Disease Clinical Trial
This Phase I clinical trial is the first step in testing gene therapy. This study is called a "Safety/Toxicity" study by the Food and Drug Administration, and primarily aims to determine whether the experimental protocol is safe…
- Trial name
- NCT00017940
- Testing
- Human Nerve Growth Factor
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- The Shiley Family Trust
Dementia
Dementia Communication Training Program for Novice Home Care Workers
This study aims to evaluate the effects of a dementia communication training program using a real-time interactive virtual trainer among novice home care workers.
- Trial name
- NCT07244497
- Testing
- virtual trainer-based dementia communication training, scenario-based discussions dementia communication training
- Where
- Taiwan
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Tzu Chi University
Vascular Cognitive Impairment no Dementia
Memory and Antioxidants in Vascular Impairment Trial
This is a 24-week randomized, double-blind, placebo-controlled parallel group design study involving Vascular cognitive impairment-no dementia (VCIND) patients to evaluate the efficacy and safety of oral NAC supplementation…
- Trial name
- NCT03306979
- Testing
- N Acetylcysteine
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Sunnybrook Health Sciences Centre
AIDS Dementia Complex
Maraviroc and NeuroAIDS Pathogenesis
Maraviroc is an antiretroviral medication that may help in improving mental function in HIV infected patients with mental problems by decreasing inflammatory tendencies.
- Trial name
- NCT02159027
- Testing
- Maraviroc
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 48 people
- Sponsor
- University of Hawaii
Dementia
Adverse Drug Reactions in Older Subjects
Objective: To identify risk factors for the occurrence of adverse drug reactions (ADRs) based on geriatric evaluation. Design: Longitudinal prospective study from May 2010 to November 2011.
- Trial name
- RiskofADR (NCT03623542)
- Where
- France
- Volunteers
- 293 people
- Sponsor
- CHU de Reims
Alzheimer's Disease, Huntington's Disease
A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin
To estimate the absorption, safety, and tolerability of a dimebon transdermal solution relative to the dimebon immediate release oral formulation.
- Trial name
- NCT00990613
- Testing
- Dimebon IR, Dimebon Transdermal
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Pfizer
Mild Cognitive Impairment
Computer Games to Prevent Mild Cognitive Impairment and Dementia
The aim of the study is to show that regular playing with the logic games developed in the framework of the M3W (Mental Wellness Toolset) project (https://m3w-project.eu/) can prevent mild cognitive impairment (MCI) and dementia.
- Trial name
- NCT02310620
- Testing
- Cognitive training
- Where
- Hungary
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Semmelweis University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.